Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • organ fibrosis
    • HGF/c-met pathway
  • pipeline
    • ANG-3070
    • ANG-3777
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
      • historic price lookup
    • analyst coverage
    • press releases
    • events & presentations
    • sec filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

Member Category: Board of Directors

Karen Wilson

Karen Wilson

Gilbert S. Omenn, MD, PhD

Gilbert S. Omenn, MD, PhD

Allen R. Nissenson, MD

Allen R. Nissenson, MD

Victor F. Ganzi, JD

Victor F. Ganzi, JD

Itzhak Goldberg, MD, FACR

Itzhak Goldberg, MD, FACR

Jay Venkatesan, MD, MBA

Jay Venkatesan, MD, MBA

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2022 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | BOSTON | AUSTRALIA